Answer
During Spravato (esketamine hydrochloride) treatment, monitor for urinary tract and bladder symptoms throughout the course of treatment and refer to an appropriate healthcare provider if symptoms persist.
Sources for this answer
- Spravato 28 mg nasal spray, solutionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.4 Special warnings and precautions for use · Version 12Document updated
Sources checked